← Back to list
Genetic Testing for Hereditary Cardiovascular Disease - Medicare Advantage (Revised)
Effective date
Sep 1, 2026
Identified
Sep 2, 2026
Summary
This is a revised Medicare Advantage policy for genetic testing in hereditary cardiovascular disease, effective September 1, 2026. The policy covers genetic testing for inherited cardiomyopathies, channelopathies, familial hypercholesterolemia, and Marfan syndrome, with coverage determinations based on CMS National Coverage Determinations and MAC-specific Local Coverage Determinations. Billing teams must identify the patient's MAC jurisdiction to apply the correct LCD requirements and coding guidelines.
Get alerts when payers change rules like this one
We check Humana and other payers every day and email you when a change matches your specialty and state.
Get Humana alertsPolicy Monitoring is free. No card required.
What to do
Action · 7 steps
01Before September 1, 2026.
02Billing team must map all service locations to their applicable Medicare Administrative Contractor (MAC) jurisdiction (J5, J8, J6, JK, J15, JE, JF, JH, JL, JJ, JM, JN) using the jurisdiction table provided in the policy.
03Update billing system rules to apply the correct MAC-specific LCD for genetic testing claims based on patient location—each MAC has different local coverage determinations (e.g., MolDX articles, molecular pathology procedures, cardiovascular disease testing).
04Providers and clinical staff must understand covered conditions: inherited cardiomyopathies, cardiac channelopathies (Brugada syndrome, CPVT, LQTS), familial hypercholesterolemia, and Marfan syndrome.
05Implement prior authorization workflows requiring reference to the applicable MAC's LCD before submitting genetic testing claims.
06Train billing staff on the distinction between single-gene testing, targeted multigene panels, multicondition panels, and comprehensive panels—coverage may vary by panel type and MAC.
07Cross-reference claims against the related policy documents listed (Genetic and Coagulation Testing for Noncancer Blood Disorders, Genetic Testing for Diagnosis of Inherited Conditions, Pharmacogenomics Testing).
If missed: Failure to apply correct MAC-specific requirements will result in claim denials.
Original notice
Genetic Testing for Hereditary Cardiovascular Disease - Medicare Advantage (Revised)
mcp.humana.com · Always check the source before changing claims.
Related changes
See all Humana changes →Genetic Testing for Hereditary Cardiovascular Disease - Medicare Advantage (Revised)HighEffective Jul 1, 2026 · Medicare AdvantageGenetic Testing for Hereditary Cardiovascular Disease - Medicare Advantage (Revised)MediumEffective Jul 1, 2026 · Medicare AdvantageGenetic Testing for Hereditary Cardiovascular Disease - Medicare Advantage (Revised)MediumEffective Sep 2, 2025 · Medicare AdvantageBrowse every Humana change in the policy list